No Dice | GenomeWeb

No Dice

The Wall Street Journal's Deal Book wonders why there are so few deals going on in Europe's biopharma arena -- $137 billion of health-care deals have gone down so far this year in the US. It's not for lack of trying. "One potential deal after another has fallen apart," the article says, citing companies such as Nycomed, Crucell, and Actavis that have explored sales only to have them fall through.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.